Cargando…

Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

BACKGROUND: We have previously shown that podocalyxin-like protein (PODXL) is a prognostic biomarker for poor survival in gastric and esophageal adenocarcinoma treated with surgery up-front. The aim of the present study was to assess PODXL expression in tumors from patients treated with neoadjuvant ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borg, David, Larsson, Anna H., Hedner, Charlotta, Nodin, Björn, Johnsson, Anders, Jirström, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201481/ https://www.ncbi.nlm.nih.gov/pubmed/30355278 http://dx.doi.org/10.1186/s12967-018-1668-3

Ejemplares similares

Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma
por: Borg, David, et al.
Publicado: (2016)

Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
por: Borg, David, et al.
Publicado: (2016)

High Infiltration of CD68(+)/CD163(−) Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2022)

T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival
por: Christina Svensson, Maria, et al.
Publicado: (2021)

Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma
por: Hedner, Charlotta, et al.
Publicado: (2016)

Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma
por: Fristedt, Richard, et al.
Publicado: (2014)

Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
por: Svensson, Maria C., et al.
Publicado: (2019)

Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma
por: Heby, Margareta, et al.
Publicado: (2015)

The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2017)

High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death
por: Jonsson, Liv, et al.
Publicado: (2014)

Tumor-Associated CD68(+), CD163(+), and MARCO(+) Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
por: Jeremiasen, Martin, et al.
Publicado: (2020)

SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma
por: Hedner, Charlotta, et al.
Publicado: (2014)

Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases
por: Larsson, Anna H, et al.
Publicado: (2013)

Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer
por: Nodin, Björn, et al.
Publicado: (2012)

Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer
por: Larsson, Anna, et al.
Publicado: (2012)

Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas
por: Heby, Margareta, et al.
Publicado: (2020)

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
por: Larsson, A, et al.
Publicado: (2011)

Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study
por: Boman, Karolina, et al.
Publicado: (2017)

Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer
por: Larsson, Anna H., et al.
Publicado: (2016)

Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer
por: Boman, K, et al.
Publicado: (2013)

Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma
por: Heby, Margareta, et al.
Publicado: (2018)

Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome
por: Lundgren, Sebastian, et al.
Publicado: (2019)

Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma
por: Andersson, Gustav, et al.
Publicado: (2019)

Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens
por: Wahlin, Sara, et al.
Publicado: (2019)

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Izadi, Fereshteh, et al.
Publicado: (2021)

Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers
por: Richards, Cathy E., et al.
Publicado: (2021)

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Arbore, Giuseppina, et al.
Publicado: (2023)

Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma
por: Elebro, Jacob, et al.
Publicado: (2016)

Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis
por: Berntsson, Jonna, et al.
Publicado: (2018)

Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition
por: Berntsson, Jonna, et al.
Publicado: (2019)

Podocalyxin as a Prognostic Marker in Gastric Cancer
por: Laitinen, Alli, et al.
Publicado: (2015)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment
por: Lundgren, Sebastian, et al.
Publicado: (2016)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype
por: Lundgren, Sebastian, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
por: Hadzitheodorou, Christina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e7e30vaapl20h03knj1blmek2g